Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- filgrastim
- levamisole
Interactions between your drugs
levamisole filgrastim
Applies to: levamisole, filgrastim
ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.
MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.
References (4)
- (2002) "Product Information. Neupogen (filgrastim)." Amgen
- (2001) "Product Information. Leukine (sargramostim)." Immunex Corporation
- (2001) "Product Information. Stemgen (ancestim)." Amgen
- (2013) "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA
Drug and food interactions
levamisole food
Applies to: levamisole
GENERALLY AVOID: Case histories have suggested that levamisole is associated with some side effects (including headache, fever, shivers, and dizziness) that suggest an disulfiram-like interaction with alcohol. These side effects could be alleviated by total abstinence from alcohol. No mechanism has been established for this interaction.
MANAGEMENT: Patients receiving levamisole should avoid alcohol.
References (3)
- (2001) "Product Information. Ergamisol (levamisole)." Janssen Pharmaceuticals
- Renoux G (1980) "The general immunopharmacology of levamisole." Drugs, 19, p. 89-99
- Renoux G (1978) "Modulation of immunity by levamisole." Pharmacol Ther [B], 2, p. 397-422
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Diflucan
Diflucan (fluconazole) is used to treat and prevent fungal infections. Includes Diflucan side ...
Zarxio
Zarxio (filgrastim-sndz) is biosimilar product used to treat neutropenia associated with ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Neulasta
Neulasta is used to stimulate neutrophil growth and reduce infection risk (manifested by febrile ...
Neupogen
Neupogen (filgrastim) is used to treat neutropenia, a lack of certain white blood cells caused by ...
Fulphila
Fulphila is used for febrile neutropenia, neutropenia associated with chemotherapy
Nivestym
Nivestym is used for bone marrow transplantation, neutropenia, neutropenia associated with ...
Nplate
Nplate is used to prevent bleeding episodes in people with chronic immune thrombocytopenic purpura ...
Udenyca
Udenyca is used for febrile neutropenia, hematopoietic syndrome of acute radiation syndrome ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.